Core Insights - PAR Technology Corporation will report its fourth quarter financial results for fiscal 2025 on February 26, 2026, with a conference call scheduled for 4:30 PM ET [1] - The company is a leading foodservice technology provider, offering a unified platform that integrates various solutions for restaurants and retailers [1] Financial Results Announcement - The financial results will be released at 4:00 PM ET, followed by an investor presentation and conference call [1] - The conference call will be available via a live webcast on the PAR Technology Investor Relations website [1] Company Overview - PAR Technology Corporation specializes in foodservice technology, providing solutions that include point-of-sale, digital ordering, loyalty programs, back-office management, payments, and hardware [1] - The company's offerings are designed to enhance operational efficiency and improve guest experiences for restaurants and retailers globally [1] Recent Developments - Jack's Family Restaurants is expanding its partnership with PAR Technology, adopting various PAR solutions across approximately 300 locations [1] - PAR Technology has agreed to acquire Bridg for $27.5 million, aiming to enhance retail and restaurant activation through improved data integration [1] - Papa John's has selected PAR Technology's solutions to transform its in-restaurant technology across 3,200 U.S. locations, marking a significant step in its digital evolution [1]

Core Viewpoint - PAR Technology Corporation has announced the acquisition of Bridg, a shopper intelligence platform, for a purchase price of $27.5 million, with potential adjustments bringing the total to a maximum of $30 million [1] Group 1: Acquisition Details - The acquisition involves substantially all assets of Bridg, which is a division of Cardlytics, Inc. [1] - The structured purchase price is set at $27.5 million, with adjustments possible that could increase the total to $30 million [1]

Executive Appointments - S&P Global appointed Matt Calderone as CFO of its mobility business, effective March 1, coming from Booz Allen where he served as CFO since 2022 and managed over $1.5 billion in M&A transactions [2] - Marathon Petroleum announced Maria Khoury as its new finance chief starting January 19, previously serving as Group CFO at Danaher and holding various leadership roles at GE [3] - Cardlytics will see the return of former CFO David Evans on January 12, who previously held the position from 2014 to 2020 and was instrumental in the company's IPO in 2018 [4] - 7 Brew has hired Matthew Dunnigan as finance chief, who previously served as CFO of Restaurant Brands International for six years [5] - SurveyMonkey appointed Lance Ludman as its new CFO, with prior experience as CFO at Benevity and DreamBox Learning [6]

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - AGM Group Holdings Inc. (AGMH) increased by 185% to $6.36 [3] - AlphaVest Acquisition Corp (ATMV) rose by 77% to $26.80 [3] - Brera Holdings PLC (BREA) saw a 20% increase to $30.00 [3] - Asset Entities Inc. (ASST) gained 18% to $4.54 [3] - 22nd Century Group, Inc. (XXII) also increased by 18% to $2.08 [3] - Millennium Group International Holdings Limited (MGIH) rose by 16% to $2.84 [3] - Robo.ai Inc. (AIIO) increased by 11% to $2.17 [3] - Butterfly Network, Inc. (BFLY) saw a 10% rise to $2.10 [3] - GrafTech International Ltd. (EAF) increased by 9% to $13.91 [3] - Cardlytics, Inc. (CDLX) rose by 8% to $2.99 [3] Premarket Losers - ECD Automotive Design, Inc. (ECDA) decreased by 14% to $3.70 [4] - Champions Oncology, Inc. (CSBR) fell by 8% to $6.11 [4] - Beam Global (BEEM) saw an 8% decline to $2.79 [4] - Fathom Holdings Inc. (FTHM) decreased by 8% to $2.19 [4] - Ventyx Biosciences, Inc. (VTYX) fell by 7% to $2.20 [4] - SciSparc Ltd. (SPRC) decreased by 6% to $4.35 [4] - Lightwave Logic, Inc. (LWLG) fell by 6% to $3.45 [4] - Jasper Therapeutics, Inc. (JSPR) decreased by 6% to $2.43 [4] - StableX Technologies, Inc. (SBLX) fell by 5% to $5.67 [4] - Galecto, Inc. (GLTO) decreased by 5% to $2.70 [4]

Group 1: ESSA Pharma Inc. (NASDAQ:EPIX) - The class period for the lawsuit is from December 12, 2023, to October 31, 2024, with a lead plaintiff deadline of March 25, 2025 [2] - The complaint alleges that defendants made materially false and misleading statements regarding the efficacy of masofaniten in combination with enzalutamide for treating prostate cancer [2] - Key allegations include that the combination treatment had no clear efficacy benefit over enzalutamide alone and that the M-E Combination Study was unlikely to meet its primary endpoint [2] Group 2: Cardlytics, Inc. (NASDAQ:CDLX) - The class period for the lawsuit is from March 14, 2024, to August 7, 2024, with a lead plaintiff deadline of March 25, 2025 [3] - The lawsuit claims that defendants made false statements regarding the company's ability to increase billings in line with rising consumer engagement [3] - Allegations include that changes to Cardlytics' Ads Decision Engine led to "underdelivery" of budgets and customer billing estimates, resulting in misleading positive statements about the company's prospects [3] Group 3: Novo Nordisk A/S (NYSE:NVO) - The class period for the lawsuit is from November 2, 2022, to December 19, 2024, with a lead plaintiff deadline of March 25, 2025 [4] - The complaint alleges that defendants created a false impression of reliable information regarding the success of the phase 3 CagriSema study on obesity [4] - Key points include that the optimistic claims about achieving at least 25% weight loss were misleading and that the study's flexible protocol limited its ability to provide effective weight loss data [4] Group 4: Crocs, Inc. (NASDAQ:CROX) - The class period for the lawsuit is from November 3, 2022, to October 28, 2024, with a lead plaintiff deadline of March 24, 2025 [6] - The lawsuit alleges that defendants misrepresented the revenue growth of HEYDUDE, claiming it was driven by management's decision to stock wholesalers aggressively, regardless of retail demand [6]

Core Viewpoint - A class action securities lawsuit has been filed against Cardlytics, Inc. for alleged securities fraud affecting investors between March 14, 2024, and August 7, 2024 [1] Group 1: Lawsuit Details - The lawsuit claims that Cardlytics made false statements regarding consumer engagement and its ability to increase billings, leading to a significant risk of revenue growth slowing or declining [2] - It is alleged that changes to the Ads Decision Engine resulted in "under-delivery" of budgets and customer billing estimates, making the company's positive statements materially misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cardlytics, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions during a specified class period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 14, 2024, to August 7, 2024 [2]. - Allegations include that the company failed to disclose that increased consumer engagement led to higher consumer incentives, and that it could not increase billings in line with this engagement [2]. - There is a significant risk that revenue growth would slow or decline due to these factors, and the changes to the Ads Decision Engine resulted in "under-delivery" of budgets and billing estimates [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially be appointed as lead plaintiff [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock price [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cardlytics, Inc. due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation and Claims - The law firm is urging investors who suffered losses exceeding $50,000 in Cardlytics between March 14, 2024, and August 7, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Cardlytics, with a deadline of March 25, 2025, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Cardlytics - The complaint alleges that Cardlytics and its executives made false or misleading statements and failed to disclose critical information regarding consumer engagement and revenue growth [4]. - Specific allegations include the inability to increase billings in line with consumer engagement and the risk of slowing or declining revenue growth [4]. Group 3: Financial Performance and Stock Impact - On May 8, 2024, Cardlytics reported an 8% year-over-year revenue increase, which was overshadowed by a 20.2% rise in consumer incentives, leading to a stock price drop of $5.33 (36.5%) to $9.27 per share [5]. - Following the release of second quarter 2024 results on August 7, 2024, which showed a 9% year-over-year revenue decrease to $69.6 million, the stock price fell by $3.94 (57.1%) to $2.96 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against Cardlytics, Inc. for alleged securities fraud affecting investors between March 14, 2024, and August 7, 2024 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants made false statements regarding consumer engagement and its impact on revenue, indicating that increased consumer engagement led to higher consumer incentives but did not result in proportional billings [2]. - It is alleged that there was a significant risk of slowing or declining revenue growth due to the inability to increase billings in line with consumer engagement [2]. - The changes to the Ads Decision Engine, which were intended to boost consumer engagement, resulted in "under-delivery" of budgets and customer billing estimates, misleading investors about the company's operational health [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, emphasizing that there is no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].